Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial - Seite 3

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS:

Nisha Deo
Global Media Relations
Boston Scientific Corporation
[phone] (office)
[e-mail]

Simonetta Balbi
PR and Corporate Communication EMEA
Boston Scientific Corporation
+ 39-3387936422 (mobile)
+ 39-0106060281 (direct)
[e-mail]

Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
[phone] (office)
[e-mail]